

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5540817

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PAUL WIDBOOM	10/16/2018
RECEIVING PARTY DATA	
Name:	ADIMAB LLC
Street Address:	7 LUCENT DRIVE
City:	LEBANON
State/Country:	NEW HAMPSHIRE
Postal Code:	03766
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16420511
CORRESPONDENCE DATA	
Fax Number:	(617)217-4699
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172174700
Email:	IPBoston.Docketing@nelsonmullins.com, jackeline.flores@nelsonmullins.com
Correspondent Name:	NELSON MULLINS RILEY & SCARBOROUGH LLP
Address Line 1:	ONE POST OFFICE SQUARE
Address Line 2:	FLOOR 30, SUITE 3000
Address Line 4:	BOSTON, MASSACHUSETTS 02109-2127
ATTORNEY DOCKET NUMBER:	CTN-006CNDV3
NAME OF SUBMITTER:	AMY E. MANDRAGOURAS, ESQ.
SIGNATURE:	/Amy E. Mandragouras, Esq./
DATE SIGNED:	05/24/2019
Total Attachments: 4	
source=Adimab Inventor to Adimab Executed Assignment_CTN-006CNDV3 #page1.tif	
source=Adimab Inventor to Adimab Executed Assignment_CTN-006CNDV3 #page2.tif	
source=Adimab Inventor to Adimab Executed Assignment_CTN-006CNDV3 #page3.tif	
source=Adimab Inventor to Adimab Executed Assignment_CTN-006CNDV3 #page4.tif	

ASSIGNMENT BY INVENTOR

I, Paul WIDBOOM, of Lebanon, New Hampshire, for good and valuable consideration paid to me by

Adimab LLC

a Limited Liability Company of Delaware, having its principal place of business at 7 Lucent Drive, Lebanon, New Hampshire 03766, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Adimab LLC

(hereinafter "ASSIGNEE") its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF

(hereinafter "SUBJECT MATTER") described in an application

Executed by me of even date herewith and about to be filed

or

Application No. 16/032639, filed on July 11, 2018; and International Application No. PCT/US2018/041612, filed on July 11, 2018

This application claims the benefit of the following provisional application(s):

Provisional Application No. 62/577259, filed on October 26, 2017
 Provisional Application No. 62/577257, filed on October 26, 2017
 Provisional Application No. 62/568231, filed on October 4, 2017
 Provisional Application No. 62/531259, filed on July 11, 2017
 Provisional Application No. 62/531190, filed on July 11, 2017

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executors and administrators, with said Limited Liability Company and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Limited Liability Company, with specifications and claims in such form as shall be approved by the counsel of said Limited Liability Company and to vest and confirm in said Limited Liability Company, its successors and assigns, the legal title to all such patents.

I agree to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. I further agree to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Limited Liability Company, its successors and assigns.

And I do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

ASSIGNOR:

10/14/18
Date

Paul Widboom
Paul Widboom

Witness:

10/16/18
Date

[Signature]

ASSIGNEE:


I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Adimab LLC, the Assignee, of which I am an authorized signatory.

ERIC KRAULAND

Signatory Name (print)

CHIEF SCIENTIFIC OFFICER


Signatory Title (print)



Signature, Adimab LLC

Date: October 16th 2018

Witness:


Signature

10/16/18
Date